In response to recent controversies, SOFTCARE has issued a formal statement to set the record straight and reassure its partners and consumers. The company strongly denies the accusations, which it considers unfounded, and commits to a process of complete transparency.

The company has instructed its lawyers to initiate legal proceedings following statements made by Moussa Diallo, Director of Market Inspection and Surveillance at the Senegalese Pharmaceutical Regulatory Agency (ARP). SOFTCARE considers the accusations of attempted bribery leveled against it by Diallo to be "defamatory and unfounded." The company's management believes these remarks seriously damage the brand's reputation and public trust. It now relies on the competent judicial authorities to establish the truth in strict accordance with the law.

Full support for the official investigations

In addition to its legal action, SOFTCARE supports the investigations being conducted by the Senegalese government and the Joint Product Quality Investigation Group. The company is confident that these investigations, based on objective facts, will clarify the situation impartially. It is committed to fully cooperating with the authorities and urges the public to await the conclusions of the official report.

In a proactive approach, SOFTCARE has taken samples of its products from the market for independent analysis. The key points regarding product safety are as follows:

-The initial results available confirm that the products comply with the applicable quality requirements.

-Other analyses are currently being carried out in reference laboratories and their results will be made public as soon as they are finalized.

-Measures to support and protect the customer experience have been deployed to address user concerns.

The company invites its customers to consult its official social media channels for more details on these measures and expresses its gratitude for the continued support of its customers.